As of Jul 31
| +0.80 / +4.88%|
The 5 analysts offering 12-month price forecasts for Amicus Therapeutics Inc have a median target of 16.00, with a high estimate of 19.00 and a low estimate of 15.00. The median estimate represents a -6.92% decrease from the last price of 17.19.
The current consensus among 5 polled investment analysts is to Buy stock in Amicus Therapeutics Inc. This rating has held steady since July, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.